Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-06
2005-12-06
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S325000
Reexamination Certificate
active
06972296
ABSTRACT:
A method for the inhibition of the binding of α4β1integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1is involved.
REFERENCES:
patent: 5192746 (1993-03-01), Lobl et al.
patent: 5484946 (1996-01-01), Abood et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5521179 (1996-05-01), Bernstein et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5710153 (1998-01-01), Ohmoto et al.
patent: 5721366 (1998-02-01), Abood et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5821231 (1998-10-01), Arrhenius et al.
patent: 5936065 (1999-08-01), Arrhenius et al.
patent: 6096773 (2000-08-01), Scott et al.
patent: 6194448 (2001-02-01), Biediger et al.
patent: A-92421/98 (1999-10-01), None
patent: 26 14 189 (1977-10-01), None
patent: 0 341 915 (1989-05-01), None
patent: 0 355 819 (1989-08-01), None
patent: 0 355 819 (1990-02-01), None
patent: 0 422 938 (1991-04-01), None
patent: 0 512 831 (1992-07-01), None
patent: 0 508 798 (1992-09-01), None
patent: 7-304735 (1995-11-01), None
patent: WO 9422820 (1994-10-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 96/06108 (1996-02-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 97/43650 (1997-11-01), None
patent: WO 98/04247 (1998-02-01), None
patent: WO 98/04913 (1998-02-01), None
patent: WO 98/11896 (1998-03-01), None
patent: WO 99/06434 (1999-02-01), None
patent: WO 99/10313 (1999-03-01), None
patent: WO 99/20272 (1999-04-01), None
patent: WO 99/24398 (1999-05-01), None
patent: WO 99/64897 (1999-06-01), None
patent: WO 00/17197 (1999-09-01), None
patent: WO 99/52493 (1999-10-01), None
patent: WO 00/17197 (2000-03-01), None
patent: WO 00/61631 (2000-10-01), None
patent: WO 00/67746 (2000-11-01), None
patent: WO 00/68188 (2000-11-01), None
patent: WO 01/46190 (2001-06-01), None
patent: WO 91/13862 (2002-08-01), None
Andrian et. al., “Alpha 4 Integrins as Therapeutics Targets in Autoimmune Disease” N England J Med 348; 1, Jan. 2, 2003.
Greene, et. al., Protective Groups in Organic Synthesis, John Wiley & Sons, pp. 271-271.
Sidduri et al. “Synthesis of 4-pyrimidinyl . . . ” CA 135:33648 (2001).
L. Ismaili, et al; Synthesis of New Pyrazolo(4,3-c)quinoline-3-one Derivatives and Some Oxazolo(4,5-c)quinoline-2,4-diones: Journal of Hetercyclic Chemistry, vol. 36, No. 3, 1999, pp. 719-722; France.
J. J. Panouse, et al.; Relations structures-activities des immunomodulateurs. Apport de la modelisation moleculaire; Annales Pharmaceutiques Francaises, vol. 58, No. 5, 2000, pp. 291-302.
Walter, D. Eric et al., “Genetically Evolved Receptor Models: A Computational Approach to Construction of Receptor Model”, Journal of Medical Chemistry, 47(16):2527-2536, Apr. 7, 1994.
D. Eric Walters and R. Michael Hinds, Genetically Evolved Receptor Models: A Computational Approach to Construction of Receptor Models;J. Med. Chem., vol. 37, No. 16, 1994, pp. 2527-2536.
Biediger Ronald J.
Chen Qi
Decker E. Radford
Holland George W.
Kassir Jamal M.
Chang Celia
Encysive Pharmaceuticals Inc.
LandOfFree
Carboxylic acid derivatives that inhibit the binding of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxylic acid derivatives that inhibit the binding of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid derivatives that inhibit the binding of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487995